RhoVac retains international investment bank as advisor for desired RV001 transaction
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today, October 11, 2021, that it has retained the services of Stifel Nicolaus Europe Limited (“Stifel”), a global investment bank, as its exclusive financial adviser in connection with the planning, execution and closing of a potential transaction or partnership deal (a “transaction”). Such a transaction would be pivotal for further development and commercialisation of the company’s lead drug candidate, RV001. RhoVac will seek a potential transaction assuming a positive outcome in the ongoing clinical phase IIb trial,